- ISPOR Latin America Summit 2019
ISPOR Latin America 2019
- Abstract Information
- Exhibits & Sponsorship
ISPOR Europe 2019
- Abstract Information
- Short Courses
- Exhibits & Sponsorship
- ISPOR Summit 2019
- ISPOR 2019
- ISPOR Warsaw 2019
- ISPOR Europe 2018
- ISPOR Summit 2018
- ISPOR Dubai 2018
- ISPOR Asia Pacific 2018
- ISPOR 2018
- ISPOR Europe 2017
- ISPOR Latin America 2017
- ISPOR Asia Pacific 2016
- Submit Abstract
- Exhibits & Sponsorships
- Awards & Grants
- Upcoming Conferences
Education & Training
- In-Person Training
- Introduction to Outcomes Research
- Introduction to Systematic Reviews & Meta-Analysis
- Systematic Review & Meta-Analysis: Applications
- Introduction to Pharmacoeconomics
- Cost-of-Illness/Cost-Estimation (COI/CE)
- Cost-Minimization/Cost-Consequence (CMA/CCA)
- Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA)
- Modeling Health Care Costs – Part I: Characteristics of Health Care Costs
- Modeling Health Care Costs – Part II: Methods and Guidelines for Estimating Health Care Costs
- Modeling Health Care Costs – Part III: Estimation from Censored Data
- Introduction to Budget Impact Analysis (BIA) - Part I
- Introduction to Budget Impact Analysis (BIA) - Part II
- Markov Model Toolkit: Concepts, Assumptions and Examples
- An Introduction to Choice-Based Conjoint Analysis (Discrete Choice Experiments)
- Health-Related Quality of Life (HRQOL) – Basics
- Patient Reported Outcomes: Analysis and Interpretation
- Patient Reported Outcomes: Instrument Development
- Item Response Theory: A Conceptual Introduction
- Preparing for Multinational Clinical Trials: Translation and Cultural Adaptations of PRO Measures
- Evidence Generation for Patient Reported Outcome (PRO) Label Claims (FDA Requirements)
- Intermediate Retrospective Observational Study - Propensity Scoring Methods
- Use of Public Survey Data in Health Outcomes Research
- Using RWE to Improve Healthcare Decision-making in Asia Pacific
- Top 10 HEOR Trends of 2019
- The Use of MCDA for HTA Agencies
- MCDA - How to Guide of Different Methods for Assessment of Rare Disease HT
- Virtualizing Long-Term Follow-Up Studies for Gene Therapy Products
- Is the FDA's New Guidance a Watershed Moment for Real-world Evidence?
- Topics in Evaluating the Cost-Effectiveness of Gene Therapies
- Principles of Machine Learning for Prediction
- Distance Learning
ISPOR is strongly committed to diversity. The Society’s Strategic Plan and core values embrace excellence through encouragement and acceptance of diverse ideas, cultures, and disciplines. Research submissions are encouraged from all stakeholders and are evaluated based on merit. ISPOR also aims to reflect the diversity of its membership in all endeavors and encourages consideration of diversity in abstract submissions. Diversity dimensions include (but not limited to) gender, career stage, ethnicity, race, education, sexual orientation, region/geographic location, physical disability, and religion. Additional information can be found at the Society’s Diversity Policy.
- ISPOR workshops are designed to share novel and innovative experiences in either the conduct of pharmacoeconomics and outcomes research studies or the interpretation and use of pharmacoeconomics outcomes information in health care policy development.
- An ISPOR workshop is similar to a one-hour short course with an audience participation element.
- Standard and advanced methods topics workshop submissions follow the same review process.
- Example of a workshop proposal submission is available here.
Workshop submissions should be organized as follows:
- TITLE: Provide a title that accurately describes your workshop. The title should be in all CAPS.Examples:
- FIXING THE TOWER OF BABEL: ESTABLISHING A COMMON METRIC FOR PATIENT-REPORTED OUTCOME MEASURES
- OPTIMAL ALLOCATION OF RESOURCES IN MANAGING MEDICAL DEVICE PORTFOLIOS
- ADJUSTING FOR BETWEEN-TRIAL DIFFERENCES IN THE SCHEDULE OF ASSESSMENT FOR DISEASE PROGRESSION IN IMMUNO-ONCOLOGY AND ITS IMPACT ON INDIRECT TREATMENT COMPARISONS
- DISCUSSION LEADERS: A workshop is comprised of a minimum of 2 and a maximum of 4 discussion leaders.
- Diversity of stakeholders, work environments and/or geographic locations is strongly encouraged to provide different perspectives on the topic.
- Only 2 discussion leaders per organization is permitted
- Provide the names, degrees, positions, city, state, country and email addresses for the discussion leaders.
- PURPOSE: Provide a clear definition of the workshop’s objective. (Ensure that the purpose(s) is achievable in 60 minutes.)
- DESCRIPTION: Provide background information and details on the material to be presented. Include speaker presentation length, e.g., 10 minutes, especially if there is concern that objective cannot be met in 60 minutes. It is helpful to include which stakeholders will benefit from attending.
- LENGTH of PROPOSAL (Purpose and Description): 300 words
- AUDIENCE INTERACTIVE ELEMENT: This is an important criterion to fulfill.
- Example 1: Each speaker will present a schematic of how patient preference data are included in their respective regulatory processes. The audience will participate in the evaluation exercise drawing on the pros versus cons of each arrangement to develop an ‘ideal’ process for using this data in healthcare decision making.
- Example 2: The workshop will use real-time polling to work through the examples and conclude with an audience discussion about the opportunities and challenges of using these different methods for portfolio selection.
- Example 3: The discussion leaders will conduct a real-time test of the validity of audience members’ preferences and help the audience evaluate the implications of such validity failures for regulatory decision making.
TOPIC CATEGORIES AND SUB-CATEGORIES FOR WORKSHOP SUBMISSIONS
Select the topic/subtopic that best describes your proposal from the list below:
Clinician Reported Outcomes
Comparative Effectiveness or Efficacy
Clinician Outcomes Assessment
Relating Intermediate to Long-term Outcomes
Cost/Cost of Illness/Resource Use Studies
Budget Impact Analysis
Thresholds & Opportunity Cost
Trial-based economic evaluation
Work & Home Productivity - Indirect Costs
Value of Information
Novel & Social Elements of Value
Safety & Pharmacoepidemiology
Prevalence, Incidence, & Disease Risk Factors
Disease Classification & Coding
Approval & Labeling
Pricing Policy & Schemes
Reimbursement & Access Policy
Insurance Systems & National Health Care
Public Spending & National Health Expenditures
Coverage with Evidence Development & Adaptive Pathways
Health Disparities & Equity
Hospital and Clinical Practices
Pharmacist Interventions and Practices
Quality of Care Measurement
Treatment Patterns and Guidelines
Systems & Structure
Value Frameworks & Dossier Format
Decision & Deliberative Processes
Diagnostics & Imaging
Artificial Intelligence, Machine Learning, Predictive Analytics
Confounding, Selection Bias Correction, Causal Inference
Modeling & Simulation
PRO & Related Methods
Academic & Educational
Best Research Practices
Geographic & Regional
Adherence, Persistence, & Compliance
Stated Preference & Patient Satisfaction
Health State Utilities
Patient-reported Outcomes & Quality of Life Outcomes
Patient Behavior and Incentives
Instrument Development, Validation, & Translation
Data Protection, Integrity, & Quality Assurance
Health & Insurance Records Systems
Distributed Data & Research Networks
Reproducibility & Replicability
Pragmatic Trials & Large Simple Trials
Prospective Observational Studies
Electronic Medical & Health Records
Administrative Claims Data
Surveys & Expert Panels
Decision Modeling & Simulation
Literature Review & Synthesis
Meta-analysis & Indirect Comparisons
CRITERIA FOR EVALUATION OF WORKSHOPS:
Overall, workshop acceptance is based on the quality of the proposal and the topic’s importance for inclusion and discussion in this conference’s scientific program. Standard and advanced methods topics workshop submissions follow the same review process.
All workshop submissions are judged according to these criteria:
- The information / issue(s) presented are valuable to the health economic & outcomes researcher or the healthcare decision-maker.
- The information / issue(s) presented are novel or innovative. .
- There is a clearly defined audience interactive element in the workshop.
- The workshop purpose(s) are clearly stated.
- The purpose(s) can be achieved in the 60 minutes allotted for this workshop.
- The workshop presentation should contain original scientific content and not just report on the routine use of a single instrument or tool.
- Examples should be drawn from a number of sources and not just the presenter(s)' own studies.
- The workshop does NOT appear to be advertising the presenter's company's services or products.
[Note: ISPOR recognizes that a primary purpose of workshops is to allow the presenter(s) to demonstrate their competence in a topic or subject area. However, attendees expect a scientific discourse, so it is important that these workshops are not used as a marketing platform for the presenter's company's products or services.]